cangrelor (kengreal) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cangrelor is a P2Y12 inhibitor that has been approved as an antiplatelet drug. It is marketed in the US under the brand name Kengreal and in Europe as Kengrexal. Cangrelor is an intravenous, direct-acting reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention.   NCATS

Chemistry

  • SMILES: CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O
  • InChIKey: PAEBIVWUMLRPSK-IDTAVKCVSA-N
  • Mol. Mass: 776.37
  • ALogP: 2.85
  • ChEMBL Molecules:
    cangrelor  
    cangrelor tetrasodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$514.7690
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ar c69931mx | ar-c69931mx | ar-c69931xx | arl69931 | canegrelor | cangrelor | cangrelor tetrasodium | [dichloro-[[[(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid | kengreal | kengrexal | n(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid)

Organizations (29)

Research & Development (29)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (2)


 

Myocardial Infarction

Thrombosis

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Acute Coronary Syndrome (Phase 4)

Angina Pectoris (Phase 4)

Atherosclerosis (Phase 3)

Blood Platelet Disorders (Phase 4)

Coronary Artery Disease (Phase 4)

Healthy Volunteers (Phase 1)

Hypothermia, Induced (Phase 4)

Ischemia (Phase 3)

Lung Diseases (Phase 4)

Myocardial Infarction (Phase 4)

Neurodegenerative Diseases ()

Out-of-Hospital Cardiac Arrest (Phase 4)

Percutaneous Coronary Intervention (Phase 4)

Platelet Aggregation Inhibitors (Phase 2)

Shock, Cardiogenic (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial Organizations: 29

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue